MicroRNA-155-5p is a key regulator of allergic inflammation, modulating the epithelial barrier by targeting PKIα

Xiaoyu Wang1,2, Yanyan Chen1, Weiyuan Yuan1

  • 1Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

Cell Death & Disease
|November 27, 2019
PubMed

Insights

MicroRNA-155-5p (miR-155-5p) drives allergic skin inflammation in atopic dermatitis (AD) by targeting protein kinase inhibitor α (PKIα), affecting epithelial barrier function. Inhibiting miR-155-5p shows therapeutic potential for AD.

Area of Science:

  • Immunology
  • Dermatology
  • Molecular Biology

Background:

  • MicroRNA-155-5p (miR-155-5p) is implicated in allergic inflammation and overexpressed in atopic dermatitis (AD) skin.
  • The precise mechanism by which miR-155-5p contributes to AD pathogenesis remains unclear.

Purpose of the Study:

  • To elucidate the role of miR-155-5p in regulating allergen-induced inflammation in an AD mouse model.
  • To identify direct targets of miR-155-5p involved in AD pathogenesis.

Main Methods:

  • Utilized an atopic dermatitis mouse model and primary epithelial cell cultures.
  • Employed techniques including microRNA inhibition/overexpression, siRNA transfection, Western blotting, and fluorescence in situ hybridization.
  • Assessed epidermal thickening, inflammatory cell infiltration, cytokine secretion, and tight junction protein expression.

Main Results:

  • Silencing miR-155-5p reduced epidermal thickening, inflammatory cell infiltration, and Th2 cytokine secretion in AD models.
  • Protein kinase inhibitor α (PKIα) was identified as a direct target of miR-155-5p, with inverse correlation in AD models.
  • miR-155-5p inhibition increased PKIα and tight junction (TJ) protein expression (occludin, CLDN16) while decreasing TSLP and IL-33, suggesting improved epithelial barrier function.

Conclusions:

  • miR-155-5p directly regulates PKIα, impacting epithelial TJ expression and contributing to allergic inflammation in AD.
  • Targeting miR-155-5p presents a potential therapeutic strategy for allergic disorders like atopic dermatitis.

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K